Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815384 | 0.85 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2894685 | 0.84 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL677770 | 0.84 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6242208 | 0.82 | RAB9A (0.84) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1815533 | 0.82 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2896309 | 0.81 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11710023 | 0.81 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL677703 | 0.81 | RAB9A (0.86) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2024479 | 0.81 | HPSE (0.61) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25138816 | 0.80 | RAB9A (0.91) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1817296-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1817296-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | RAB9A 4407/4885NPC1 2449/4885SMN1; SMN2 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.